查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
大分子药物 CDMO（合同开发和製造组织）全球市场规模、份额和行业趋势分析报告：按应用、服务、最终用户、地区划分的展望和预测，2022-2028 年
市场调查报告书
商品编码
1184260

大分子药物 CDMO（合同开发和製造组织）全球市场规模、份额和行业趋势分析报告：按应用、服务、最终用户、地区划分的展望和预测，2022-2028 年

Global Large Molecule Drug Substance CDMO Market Size, Share & Industry Trends Analysis Report By Application, By Service, By End-user, By Regional Outlook and Forecast, 2022 - 2028
出版日期: | 出版商: KBV Research | 英文 278 Pages | 订单完成后即时交付

价格

到 2028 年，全球 CDMO（合同开发和製造组织）市场规模预计将达到 192 亿美元，预测期内復合年增长率为 8.7%。

因此，CDMO 的研究能力、知识和製造能力在推进药物开发方面有着巨大的需求。 因此，许多 CDMO 在生物技术和製药公司的资金和技术资产支持下从事第三方综合企业。 此外，许多客户希望 CDMO 提供专有技术，例如营销，即使在製造之后也是如此。

这主要是因为CDMO的客户群不仅是大型製药公司，还有中小型生物科技公司。 此外，许多中小型生物技术公司在没有製造经验的情况下广泛关注不断发展的药物管道。 因此，借助CDMOs的研发和製造业务，也可以快速纳入中小生物公司的业务。

COVID-19 影响分析

一些政府实施了法规，以采购足够数量的本地生产的治疗药物和疫苗。 但是，由于供应炼和锁定限制，产能尚未达到最大值。 此外，锁定限制导致劳动力减少。 这些限制显着增加了交货时间，高达四倍。 生产延迟和需求增加进一步推动了 CDMO 的增长。 因此，大流行对高分子CDMO（合同开发和製造组织）市场产生了积极影响。

市场增长因素

增加生物製剂和生物仿製药的研发

自大流行以来，许多公司投入巨资开发生物製剂和生物仿製药。 目前，包括多□、蛋白质和单克隆抗体在内的探索性生物製剂占潜在治疗候选药物的近一半。 我们还知道，生物製药公司加大了研发力度，导致许多新型生物製药正在开发或准备中。 因此，所有这些因素都在推动大分子药物 CDMO 市场的增长。

心血管疾病 (CVD) 和 CVD 相关死亡人数增加

发表在《美国心脏病学会杂誌》上的一项研究发现，心血管疾病 (CVD) 的总重量正在稳步增加死于该疾病的人数。. 这个数字还包括 2019 年全球所有死亡人数的三分之一。 统计数据强调各国迫切需要製定负担得起的公共卫生计划，重点是通过可改变的行为来降低心脏病风险。

市场製约因素

生物製剂的复杂分析表征以及严格的参数和法规

聚合物的表征非常困难。 生物製药公司需要以多种方式进行表征，包括稳定性、纯度和功能性。 大分子通常需要结合许多低分辨率和高分辨率技术来有效地验证粒子的结构。 此外，大分子在重组合成方法中会产生大量翻译后修饰 (PTM)。 因此，加大对研发和产品开发的投资正在推动大分子药物CDMO市场的增长和发展。

应用展望

大分子药物 CDMO 市场按应用分为哺乳动物、微生物和其他。 2021 年，微生物领域在大分子药物 CDMO（合同开发和製造组织）市场取得了大幅增长。 微生物系统主要用于生产用于治疗过程的重组蛋白。 市场上的大多数药物都是通过重组技术生产的，从而促进了微生物系统的生长。

服务展望

大分子药物CDMO（合同开发和製造组织）市场按服务分为合同製造和合同开发。 合同製造部门在 2021 年大分子药物 CDMO（合同开发和製造组织）市场中占据了最大的收入份额。 合同製造执行多种功能，例如目标筛选和识别、功能信息学和目标验证、临床前开发、候选优化和先导物识别。

最终用户的观点

基于最终用户，大分子药物 CDMO 市场分为生物技术公司、CRO 和其他公司。 CRO 部分在 2021 年大分子药物 CDMO 市场中增长显着。 临床研究机构需要 CDMO 支持实验室、临床、临床前和探索性服务。 对治疗各种疾病和病症的需求不断增长，这也增加了要进行的研究的数量。

区域展望

大分子原料药 CDMO 市场按地区分析，横跨北美、欧洲、亚太地区和 LAMEA。 亚太地区在 2021 年占据了大分子药物 CDMO（合同开发和製造组织）市场的最大收入份额。 熟练的劳动力、合规的法规和较低的总体成本是推动该地区将大分子药物外包给 CDMO 的主要因素。 该地区庞大的消费群体对更好的药物和治疗技术的需求日益增长。

合作伙伴关係是市场进入者采用的主要策略。 根据 Cardinal 矩阵中的分析，Boehringer Ingelheim International GmbH是大分子药物 CDMO（合同开发和製造组织）市场的先驱。 FUJIFILM Diosynth Biotechnologies Texas LLC、WuXi Biologics (Cayman), Inc 和 Eurofins Scientific SE 等公司是大分子药物 CDMO 市场的领先创新者。

内容

第一章市场范围与研究方法

  • 市场定义
  • 目的
  • 市场规模
  • 细分
    • 全球大分子药物 CDMO（合同开发和製造组织）市场，按应用分类
    • 全球大分子药物 CDMO（合同开发和製造组织）市场，按服务分类
    • 全球大分子药物 CDMO（合同开发和製造组织）市场，按最终用户分类
    • 全球大分子药物 CDMO（合同开发和製造组织）市场，按地区
  • 调查方法

第 2 章市场概述

  • 介绍
    • 概览
      • 市场构成和情景
  • 影响市场的主要因素
    • 市场驱动因素
    • 市场製约因素

第 3 章竞争分析 - 世界

  • KBV 基数矩阵
  • 近期的全行业战略发展
    • 伙伴关係、协作和合同
    • 收购与合併
    • 地域扩张
  • 关键成功策略
    • 关键关键策略：比例分配（2018-2022 年）
    • 关键战略举措：（伙伴关係、协作、合同：2019 年 4 月至 2022 年 10 月）关键参与者
    • 主要战略举措：（收购和合併：2018 年 10 月至 2022 年 8 月）主要参与者

第 4 章全球大分子药物 CDMO 市场：按应用

  • 世界哺乳动物市场：按地区
  • 全球微生物市场：按地区
  • 全球其他应用区域市场

第 5 章全球大分子药物 CDMO 市场：按服务分类

  • 全球合同製造市场：按地区分类
  • 按合同製造类型划分的全球大分子 API CDMO（合同开发和製造组织）市场
    • 全球商业市场：按地区
    • 全球临床市场：按地区
  • 全球合同开发市场：按地区
  • 全球聚合物 API CDMO 市场：按合同开发类型分类
    • 全球细胞系探索市场：按地区
    • 全球流程开发市场：按地区

第 6 章全球大分子药物 CDMO 市场：按最终用户分类

  • 生物技术公司的全球市场：按地区
  • 全球 CRO 市场：按地区
  • 世界其他地区市场

第 7 章全球大分子药物 CDMO 市场：按地区

  • 北美
    • 按国家/地区划分的北美大分子药物 CDMO（合同开发和製造组织）市场
      • 美国
      • 加拿大
      • 墨西哥
      • 其他北美地区
  • 欧洲
    • 欧洲大分子 API CDMO 市场：按国家/地区细分
      • 德国
      • 英国
      • 法国
      • 俄罗斯
      • 西班牙
      • 意大利
      • 其他欧洲
  • 亚太地区
    • 按国家/地区划分的亚太地区高分子药物 CDMO（合同开发和製造组织）市场
      • 中国
      • 日本
      • 印度
      • 韩国
      • 新加坡
      • 马来西亚
      • 其他亚太地区
  • 拉美
    • 按国家/地区划分的 LAMEA CDMO（合同开发和製造组织）市场
      • 巴西
      • 阿根廷
      • 阿联酋
      • 沙特阿拉伯
      • 南非
      • 尼日利亚
      • LAMEA 的其余部分

第八章公司简介

  • Teledyne FLIR LLC（Teledyne Technologies Incorporated）
  • Hikvision Digital Technology Co., Ltd.,（China Electronics Technology Group Corporation）
  • Axis Communications AB（Canon, Inc.）
  • Bosch Security Systems GmbH（Robert Bosch GmbH）
  • Avigilon Corporation（Motorola Solutions）
  • Hanwha Techwin Co., Ltd.（Hanwha Group）
  • Zhejiang Dahua Technology Co., Ltd.
  • Zhejiang Uniview Technologies Co., Ltd.（Hangzhou Jiaozhi Technology Co., Ltd.）

The Global Large Molecule Drug Substance CDMO Market size is expected to reach $19.2 billion by 2028, rising at a market growth of 8.7% CAGR during the forecast period.

Contract development and manufacturing organization (CDMO) that provide services for processing large molecule or biologics drug substances are referred to as large molecule drug substance CDMO. These are companies that assist customers in drug discovery via manufacturing abilities by providing services and, thus, also help the pharmaceutical industry.

Large molecules are proteins that tend to have a therapeutic effect. These are highly complex, and most biologics are composed of approximately 1300 or more amino acids. These are prepared so that they resemble human proteins. The rise in molecule drug approvals, growing infectious disease prevalence, and increasing favorability for innovative therapeutics demand more CDMO setups for the rapid development and manufacturing of drugs.

Therefore, CDMOs' research, knowledge, and manufacturing abilities are highly necessary to proceed with drug development. As such, many CDMOs engage in integrating third-party ventures, which are also propelled by biotech and pharma companies' assistance through financial and technological assets. Most customers also expect CDMOs to offer their expertise even after manufacturing, like in commercial launches.

This is mainly because CDMO's customer base has expanded beyond the big pharmaceutical companies to smaller biotech firms. Additionally, many smaller biotech companies focus extensively on evolving their drug pipelines without any manufacturing experience. Therefore, taking help from CDMOs in development and manufacturing operations also enables the early incorporation of smaller biotech firms' operations.

COVID-19 Impact Analysis

Some governments imposed regulations that resulted in the procurement of sufficient volumes of therapeutics and vaccines that were produced locally. However, production capacities were still not at their maximum because of supply chain and lockdown constraints. Disrupted supply chains interfered with the procurement of goods needed in the production processes, like the single-use plastic bags, which CDMOs use in the reactors. In addition, the lockdown constraints introduced a reduction in the workforce. These constraints resulted in a significant increase in the lead times, which increased up to four times. The delayed production and increased demand further helped in the growth of the CDMOs. Therefore, the pandemic positively impacted the large molecule drug substance CDMO market.

Market Growth Factors

Increasing Research And Development Of Biologics And Biosimilar

Since the pandemic, numerous businesses have been making significant investments in the creation of biologics and biosimilar compounds. Presently, biologics such as peptides, proteins, and monoclonal antibodies in the discovery stage are making up almost half of the candidates intended to be used as therapeutics. Biopharmaceutical businesses are increasingly putting their resources into research and development, and as a result, many novel biologics are either being developed or are in the pipeline. Hence, all of these factors aid in the growth of the large molecule drug substance CDMO market.

Growing Cardiovascular Diseases (CVD) And CVD-Induced Deaths

According to a paper published in the Journal of the American College of Cardiology that examined the total severity of cardiovascular disease (CVD) burden, the amount of people who die from (CVD) is steadily increasing. This number also includes one-third of all deaths globally in 2019. The statistics highlight the urgent need for nations to set up affordable public health initiatives that are affordable and focused on lowering heart disease risk through modifiable behaviors.

Market Restraining Factors

Complex Analytical Characterization Of Biologics And Strict Parameters And Regulations

The characterization of large molecules is extremely challenging. Biopharmaceutical companies are needed to characterize in numerous ways, including stability, purity, and function. Large molecules routinely demand a combination of many low and high-resolution techniques to validate the particle's structure efficiently. Additionally, numerous post-translational modifications (PTMs) are produced by large molecules during the recombinant synthesis method. Hence, the rise in R&D and investments in product development are boosting the growth and advancement of the large molecule drug substance CDMO market.

Application Outlook

Based on application, the large molecule drug substance CDMO market is categorized into mammalian, microbial, and others. The microbial segment procured a considerable growth rate in the large molecule drug substance CDMO market in 2021. Microbial systems are mostly utilized in the production of recombinant proteins to be used in therapeutic processes. As most of the drugs available in the market are produced through recombinant technologies, they propel the growth of microbial systems.

Service Outlook

On the basis of service, the large molecule drug substance CDMO market is divided into contract manufacturing and contract development. The contract manufacturing segment acquired the largest revenue share in the large molecule drug substance CDMO market in 2021. Contract manufacturing performs various functions like target screening and identification, functional informatics and target validation, preclinical development, and candidate optimization and lead identification.

End-User Outlook

Based on end-user, the large molecule drug substance CDMO market is segmented into biotech companies, CRO, and others. The CRO segment witnessed a considerable growth rate in the large molecule drug substance CDMO market in 2021. The clinical research organization needs the CDMOs assistance with the laboratory, clinical, preclinical, and discovery services. In addition, the rising demand for treatments of various diseases and disorders has also increased the volume of research to be conducted.

Regional Outlook

On the basis of region, the large molecule drug substance CDMO market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment garnered the maximum revenue share in the large molecule drug substance CDMO market in 2021. A skilled workforce, compliable regulations, and lower overall costs are the main factors that propel the outsourcing of large molecule drug substances to the CDMOs of this region. The presence of a considerable consumer base present in this region has increased the need for improved medicines and treatment techniques.

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Boehringer Ingelheim International GmbH is the forerunner in the Large Molecule Drug Substance CDMO Market. Companies such as FUJIFILM Diosynth Biotechnologies Texas LLC, WuXi Biologics (Cayman), Inc., Eurofins Scientific SE are some of the key innovators in Large Molecule Drug Substance CDMO Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.

Recent Strategies Deployed in Large Molecule Drug Substance CDMO Market

Partnerships, Collaborations and Agreements:

Oct-2022: WuXi partnered with Toregem BioPharma, a Japan-based biotechnology company, primarily into providing therapeutic agents meant for designing dental regenerative medicines. The partnership involves developing TRG035, an antibody meant for the treatment of congenital adentia. The partnership aligns with WuXi's aim to help global partners innovate new biologics solutions for patients worldwide.

Oct-2022: FUJIFILM Diosynth Biotechnologies collaborated with RoosterBio, a US-based biotechnology company, primarily into providing stem cell products. The collaboration involves GMP manufacturing of exosome and cell therapies. The collaboration allows FUJIFILM to offer comprehensive cell therapy CDMO services to its customers.

Dec-2021: WuXi partnered with ImmuneOncia, a South-Korea based Biotechnology Company, primarily into providing immunotherapies intended for the treatment of different types of cancer. The partnership involves leveraging WuXi's cell line development, bioassay development, cell culture development, and biologics manufacturing to develop bio specific antibodies. The antibody targets Programmed death-ligand 1 (PD-L1), and Cluster of Differentiation 47 (CD47).

Sep-2021: Boehringer teamed up with Twist Bioscience, a US-based synthetic biology company. The collaboration involves combining Twist's skill in generating potent, diverse therapeutic antibodies and Boehringer's expertise in drug discovery and development, which would enhance Boehringer's ability to better serve its clients and patients.

Apr-2021: Samsung Biologics teams up with TG Therapeutics, a US-based biotechnology company. The collaboration involves expansion of contract manufacturing for TG Therapeutics' ublituximab, an antigen meant for use in lymphoma, leukemia, and multiple sclerosis. This collaboration aligns with Samsung Biologics' vision to better serve humanity by bringing required treatments to the patients.

Jan-2021: Boehringer partnered with Google, a US-based global technology company. The partnership involves integrating Boehringer's competence in computer-based drug design and silico modeling with Google's expertise in algorithms and quantum computers to work on R & D. The partnership aims to advance R & D processes, thereby introducing more medical developments.

Oct-2020: WuXi collaborated with AB2 Bio, a Switzerland-based drug development and discovery company. The collaboration involves advancing Commercial-Scale Manufacturing of Tadekinig alfa, an IL-18 binding protein meant for monogenic Hemophagocytic Lymphohistiocytosis (HLH). Based on the agreement, AB2 Bio would transfer commercial manufacturing of Tadekinig alfa to WuXi.

Sep-2020: Samsung Biologics signed an agreement with AstraZeneca, a UK-based public company, primarily into marketing drugs for several diseases including, gastrointestinal, respiratory, cancer, etc. The agreement involves Samsung Biologics providing large-scale manufacturing of drug substances and drug products supporting AstraZeneca's biologics therapeutics. The agreement aligns with Samsung Biologics' purpose to support clients bring out innovative solutions.

May-2020: Rentschler Biopharma collaborated with Genmab, a Denmark-based biotechnology company. The collaboration involves a business model that aligns with the expansion strategy of Rentschler Biopharma's U.S. site in Milford, MA, and aims to manufacture and process the development of bispecific antibodies built on Genmab's DuoBody® technology platform.

Feb-2020: Catalent signed a contract with Zumutor Biologics, a US-based biotechnology company, primarily into providing NK cell therapeutics. The agreement involves manufacturing Zumutor's ZM008 meant for solid tumor treatment.

Acquisitions and Mergers:

Aug-2022: Catalent acquired Metrics Contract Services (Metrics), a US-based organization, primarily into providing contract development and manufacturing services for the medical sector. The acquisition advances Catalent's ability to better serve its clients, particularly those clients with R & D pipelines having rare, orphan, diseases for oncology and other therapeutic areas.

Apr-2022: Catalent took over a manufacturing facility in Oxfordshire from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.). The new facility enables Catalent to join forces with the biomedical science community, thereby furnishing opportunities to reshape innovation, and ideas into treatment for patients.

Feb-2022: Recipharm took over GenIbet, a Portuguese company, primarily into providing CDMO services. The acquisition strengthens Recipharm's plan to expand in the Biologics market, particularly in drug substance manufacturing of novel ATMPs.

Feb-2022: Recipharm took over Arranta Bio, a US-based company, primarily into supporting the development of health therapies. This acquisition forms a keystone in Recipharm's plan to furnish drug developers with CDM services. Moreover, the acquisition expands Recipharm's presence in the US.

Jan-2022: Samsung Biologics acquired the remaining share of Biogen in Samsung Bioepis, a Joint Venture between Biogen and Samsung Biologics. The acquisition would advance development in therapeutics R&D and biosimilars.

Dec-2021: Eurofins acquired Genetic Lab, a Japanese company, primarily into pathological diagnostics services. This acquisition complements Eurofins' global network of clinical diagnostic laboratories and further boosts Eurofins' Asia expansion.

Sep-2021: Boehringer took over Abexxa Biologics, a US-based biotechnology company. The acquisition strengthens Boehringer's devotion towards the discovery of tumor-antigen, and Abexxa's expertise in antigen discovery and antibody generation complements Boehringer's current approach to enable immune-targeting of cancer cells.

Aug-2021: AGC Biologics acquired a commercial facility in Longmont, Colorado, USA from Novartis Gene Therapies. The acquisition expands AGC's manufacturing capacity supporting its global end-to-end Cell and Gene Therapy (C>) offerings and further expanding cell and gene therapy presence in the US.

Feb-2020: Siegfried took over two manufacturing sites in Spain from Novartis. This acquisition expands Siegfried's global manufacturing network and aligns with its corporate strategy EVOLVE. The two new manufacturing facilities complement Siegfried's current operations in drug products.

Geographical Expansions:

Nov-2022: WuXi opened a new manufacturing facility in Fengxian, Shanghai. The facility is a Contract Research, Development, and Manufacturing (CRDMO) center, which would provide end-to-end services including process development, drug product development, analytical development, clinical drug substance, etc. The CRDMO center would enhance manufacturing and development capacity and would support the development of new biologics programs.

Oct-2022: WuXi expanded its manufacturing facilities network, by opening a new facility in Shijiazhuang, Hebei Province, China. The new facility is a Contract Research, Development and Manufacturing Organization (CRDMO) center, named MFG8. MFG8 aligns with the company's foundation for commencing any project within 4 weeks and allows WuXi to better serve evolving needs for drug substance services.

Oct-2022: Catalent expanded its geographical footprint by setting up a new facility in Kansas City, Missouri. The expansion includes setting up two new analytical development laboratories to fulfill evolving demands of assay development.

Scope of the Study

Market Segments covered in the Report:

By Application

  • Mammalian
  • Microbial
  • Others

By Service

  • Contract Manufacturing
    • Commercial
    • Clinical
  • Contract Development
    • Cell Line Development
    • Process Development

By End-user

  • Biotech Companies
  • CRO
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Eurofins Scientific SE
  • WuXi Biologics (Cayman), Inc
  • Catalent, Inc.
  • Boehringer Ingelheim International GmbH
  • FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation)
  • Samsung Biologics Co., Ltd. (Samsung Group)
  • Rentschler Biopharma SE
  • AGC Biologics, Inc. (AGC, Inc.)
  • Recipharm AB (EQT AB)
  • Siegfried Holding AG

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Large Molecule Drug Substance CDMO Market, by Application
    • 1.4.2 Global Large Molecule Drug Substance CDMO Market, by Service
    • 1.4.3 Global Large Molecule Drug Substance CDMO Market, by End-user
    • 1.4.4 Global Large Molecule Drug Substance CDMO Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Acquisition and Mergers
    • 3.2.3 Geographical Expansions
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
    • 3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2019, Apr- 2022, Oct) Leading Players
    • 3.3.3 Key Strategic Move: (Acquisitions and Mergers : 2018, Oct - 2022, Aug) Leading Players

Chapter 4. Global Large Molecule Drug Substance CDMO Market by Application

  • 4.1 Global Mammalian Market by Region
  • 4.2 Global Microbial Market by Region
  • 4.3 Global Other Application Market by Region

Chapter 5. Global Large Molecule Drug Substance CDMO Market by Service

  • 5.1 Global Contract Manufacturing Market by Region
  • 5.2 Global Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
    • 5.2.1 Global Commercial Market by Region
    • 5.2.2 Global Clinical Market by Region
  • 5.3 Global Contract Development Market by Region
  • 5.4 Global Large Molecule Drug Substance CDMO Market by Contract Development Type
    • 5.4.1 Global Cell Line Development Market by Region
    • 5.4.2 Global Process Development Market by Region

Chapter 6. Global Large Molecule Drug Substance CDMO Market by End-user

  • 6.1 Global Biotech Companies Market by Region
  • 6.2 Global CRO Market by Region
  • 6.3 Global Others Market by Region

Chapter 7. Global Large Molecule Drug Substance CDMO Market by Region

  • 7.1 North America Large Molecule Drug Substance CDMO Market
    • 7.1.1 North America Large Molecule Drug Substance CDMO Market by Application
      • 7.1.1.1 North America Mammalian Market by Country
      • 7.1.1.2 North America Microbial Market by Country
      • 7.1.1.3 North America Other Application Market by Country
    • 7.1.2 North America Large Molecule Drug Substance CDMO Market by Service
      • 7.1.2.1 North America Contract Manufacturing Market by Country
      • 7.1.2.2 North America Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
        • 7.1.2.2.1 North America Commercial Market by Country
        • 7.1.2.2.2 North America Clinical Market by Country
      • 7.1.2.3 North America Contract Development Market by Country
      • 7.1.2.4 North America Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.1.2.4.1 North America Cell Line Development Market by Country
        • 7.1.2.4.2 North America Process Development Market by Country
    • 7.1.3 North America Large Molecule Drug Substance CDMO Market by End-user
      • 7.1.3.1 North America Biotech Companies Market by Country
      • 7.1.3.2 North America CRO Market by Country
      • 7.1.3.3 North America Others Market by Country
    • 7.1.4 North America Large Molecule Drug Substance CDMO Market by Country
      • 7.1.4.1 US Large Molecule Drug Substance CDMO Market
        • 7.1.4.1.1 US Large Molecule Drug Substance CDMO Market by Application
        • 7.1.4.1.2 US Large Molecule Drug Substance CDMO Market by Service
          • 7.1.4.1.2.1 US Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.1.4.1.2.2 US Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.1.4.1.3 US Large Molecule Drug Substance CDMO Market by End-user
      • 7.1.4.2 Canada Large Molecule Drug Substance CDMO Market
        • 7.1.4.2.1 Canada Large Molecule Drug Substance CDMO Market by Application
        • 7.1.4.2.2 Canada Large Molecule Drug Substance CDMO Market by Service
          • 7.1.4.2.2.1 Canada Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.1.4.2.2.2 Canada Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.1.4.2.3 Canada Large Molecule Drug Substance CDMO Market by End-user
      • 7.1.4.3 Mexico Large Molecule Drug Substance CDMO Market
        • 7.1.4.3.1 Mexico Large Molecule Drug Substance CDMO Market by Application
        • 7.1.4.3.2 Mexico Large Molecule Drug Substance CDMO Market by Service
          • 7.1.4.3.2.1 Mexico Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.1.4.3.2.2 Mexico Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.1.4.3.3 Mexico Large Molecule Drug Substance CDMO Market by End-user
      • 7.1.4.4 Rest of North America Large Molecule Drug Substance CDMO Market
        • 7.1.4.4.1 Rest of North America Large Molecule Drug Substance CDMO Market by Application
        • 7.1.4.4.2 Rest of North America Large Molecule Drug Substance CDMO Market by Service
          • 7.1.4.4.2.1 Rest of North America Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.1.4.4.2.2 Rest of North America Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.1.4.4.3 Rest of North America Large Molecule Drug Substance CDMO Market by End-user
  • 7.2 Europe Large Molecule Drug Substance CDMO Market
    • 7.2.1 Europe Large Molecule Drug Substance CDMO Market by Application
      • 7.2.1.1 Europe Mammalian Market by Country
      • 7.2.1.2 Europe Microbial Market by Country
      • 7.2.1.3 Europe Other Application Market by Country
    • 7.2.2 Europe Large Molecule Drug Substance CDMO Market by Service
      • 7.2.2.1 Europe Contract Manufacturing Market by Country
      • 7.2.2.2 Europe Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
        • 7.2.2.2.1 Europe Commercial Market by Country
        • 7.2.2.2.2 Europe Clinical Market by Country
      • 7.2.2.3 Europe Contract Development Market by Country
      • 7.2.2.4 Europe Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.2.2.4.1 Europe Cell Line Development Market by Country
        • 7.2.2.4.2 Europe Process Development Market by Country
    • 7.2.3 Europe Large Molecule Drug Substance CDMO Market by End-user
      • 7.2.3.1 Europe Biotech Companies Market by Country
      • 7.2.3.2 Europe CRO Market by Country
      • 7.2.3.3 Europe Others Market by Country
    • 7.2.4 Europe Large Molecule Drug Substance CDMO Market by Country
      • 7.2.4.1 Germany Large Molecule Drug Substance CDMO Market
        • 7.2.4.1.1 Germany Large Molecule Drug Substance CDMO Market by Application
        • 7.2.4.1.2 Germany Large Molecule Drug Substance CDMO Market by Service
          • 7.2.4.1.2.1 Germany Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.2.4.1.2.2 Germany Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.2.4.1.3 Germany Large Molecule Drug Substance CDMO Market by End-user
      • 7.2.4.2 UK Large Molecule Drug Substance CDMO Market
        • 7.2.4.2.1 UK Large Molecule Drug Substance CDMO Market by Application
        • 7.2.4.2.2 UK Large Molecule Drug Substance CDMO Market by Service
          • 7.2.4.2.2.1 UK Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.2.4.2.2.2 UK Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.2.4.2.3 UK Large Molecule Drug Substance CDMO Market by End-user
      • 7.2.4.3 France Large Molecule Drug Substance CDMO Market
        • 7.2.4.3.1 France Large Molecule Drug Substance CDMO Market by Application
        • 7.2.4.3.2 France Large Molecule Drug Substance CDMO Market by Service
          • 7.2.4.3.2.1 France Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.2.4.3.2.2 France Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.2.4.3.3 France Large Molecule Drug Substance CDMO Market by End-user
      • 7.2.4.4 Russia Large Molecule Drug Substance CDMO Market
        • 7.2.4.4.1 Russia Large Molecule Drug Substance CDMO Market by Application
        • 7.2.4.4.2 Russia Large Molecule Drug Substance CDMO Market by Service
          • 7.2.4.4.2.1 Russia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.2.4.4.2.2 Russia Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.2.4.4.3 Russia Large Molecule Drug Substance CDMO Market by End-user
      • 7.2.4.5 Spain Large Molecule Drug Substance CDMO Market
        • 7.2.4.5.1 Spain Large Molecule Drug Substance CDMO Market by Application
        • 7.2.4.5.2 Spain Large Molecule Drug Substance CDMO Market by Service
          • 7.2.4.5.2.1 Spain Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.2.4.5.2.2 Spain Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.2.4.5.3 Spain Large Molecule Drug Substance CDMO Market by End-user
      • 7.2.4.6 Italy Large Molecule Drug Substance CDMO Market
        • 7.2.4.6.1 Italy Large Molecule Drug Substance CDMO Market by Application
        • 7.2.4.6.2 Italy Large Molecule Drug Substance CDMO Market by Service
          • 7.2.4.6.2.1 Italy Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.2.4.6.2.2 Italy Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.2.4.6.3 Italy Large Molecule Drug Substance CDMO Market by End-user
      • 7.2.4.7 Rest of Europe Large Molecule Drug Substance CDMO Market
        • 7.2.4.7.1 Rest of Europe Large Molecule Drug Substance CDMO Market by Application
        • 7.2.4.7.2 Rest of Europe Large Molecule Drug Substance CDMO Market by Service
          • 7.2.4.7.2.1 Rest of Europe Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.2.4.7.2.2 Rest of Europe Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.2.4.7.3 Rest of Europe Large Molecule Drug Substance CDMO Market by End-user
  • 7.3 Asia Pacific Large Molecule Drug Substance CDMO Market
    • 7.3.1 Asia Pacific Large Molecule Drug Substance CDMO Market by Application
      • 7.3.1.1 Asia Pacific Mammalian Market by Country
      • 7.3.1.2 Asia Pacific Microbial Market by Country
      • 7.3.1.3 Asia Pacific Other Application Market by Country
    • 7.3.2 Asia Pacific Large Molecule Drug Substance CDMO Market by Service
      • 7.3.2.1 Asia Pacific Contract Manufacturing Market by Country
      • 7.3.2.2 Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
        • 7.3.2.2.1 Asia Pacific Commercial Market by Country
        • 7.3.2.2.2 Asia Pacific Clinical Market by Country
      • 7.3.2.3 Asia Pacific Contract Development Market by Country
      • 7.3.2.4 Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.3.2.4.1 Asia Pacific Cell Line Development Market by Country
        • 7.3.2.4.2 Asia Pacific Process Development Market by Country
    • 7.3.3 Asia Pacific Large Molecule Drug Substance CDMO Market by End-user
      • 7.3.3.1 Asia Pacific Biotech Companies Market by Country
      • 7.3.3.2 Asia Pacific CRO Market by Country
      • 7.3.3.3 Asia Pacific Others Market by Country
    • 7.3.4 Asia Pacific Large Molecule Drug Substance CDMO Market by Country
      • 7.3.4.1 China Large Molecule Drug Substance CDMO Market
        • 7.3.4.1.1 China Large Molecule Drug Substance CDMO Market by Application
        • 7.3.4.1.2 China Large Molecule Drug Substance CDMO Market by Service
          • 7.3.4.1.2.1 China Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.3.4.1.2.2 China Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.3.4.1.3 China Large Molecule Drug Substance CDMO Market by End-user
      • 7.3.4.2 Japan Large Molecule Drug Substance CDMO Market
        • 7.3.4.2.1 Japan Large Molecule Drug Substance CDMO Market by Application
        • 7.3.4.2.2 Japan Large Molecule Drug Substance CDMO Market by Service
          • 7.3.4.2.2.1 Japan Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.3.4.2.2.2 Japan Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.3.4.2.3 Japan Large Molecule Drug Substance CDMO Market by End-user
      • 7.3.4.3 India Large Molecule Drug Substance CDMO Market
        • 7.3.4.3.1 India Large Molecule Drug Substance CDMO Market by Application
        • 7.3.4.3.2 India Large Molecule Drug Substance CDMO Market by Service
          • 7.3.4.3.2.1 India Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.3.4.3.2.2 India Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.3.4.3.3 India Large Molecule Drug Substance CDMO Market by End-user
      • 7.3.4.4 South Korea Large Molecule Drug Substance CDMO Market
        • 7.3.4.4.1 South Korea Large Molecule Drug Substance CDMO Market by Application
        • 7.3.4.4.2 South Korea Large Molecule Drug Substance CDMO Market by Service
          • 7.3.4.4.2.1 South Korea Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.3.4.4.2.2 South Korea Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.3.4.4.3 South Korea Large Molecule Drug Substance CDMO Market by End-user
      • 7.3.4.5 Singapore Large Molecule Drug Substance CDMO Market
        • 7.3.4.5.1 Singapore Large Molecule Drug Substance CDMO Market by Application
        • 7.3.4.5.2 Singapore Large Molecule Drug Substance CDMO Market by Service
          • 7.3.4.5.2.1 Singapore Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.3.4.5.2.2 Singapore Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.3.4.5.3 Singapore Large Molecule Drug Substance CDMO Market by End-user
      • 7.3.4.6 Malaysia Large Molecule Drug Substance CDMO Market
        • 7.3.4.6.1 Malaysia Large Molecule Drug Substance CDMO Market by Application
        • 7.3.4.6.2 Malaysia Large Molecule Drug Substance CDMO Market by Service
          • 7.3.4.6.2.1 Malaysia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.3.4.6.2.2 Malaysia Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.3.4.6.3 Malaysia Large Molecule Drug Substance CDMO Market by End-user
      • 7.3.4.7 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market
        • 7.3.4.7.1 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Application
        • 7.3.4.7.2 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Service
          • 7.3.4.7.2.1 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.3.4.7.2.2 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.3.4.7.3 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by End-user
  • 7.4 LAMEA Large Molecule Drug Substance CDMO Market
    • 7.4.1 LAMEA Large Molecule Drug Substance CDMO Market by Application
      • 7.4.1.1 LAMEA Mammalian Market by Country
      • 7.4.1.2 LAMEA Microbial Market by Country
      • 7.4.1.3 LAMEA Other Application Market by Country
    • 7.4.2 LAMEA Large Molecule Drug Substance CDMO Market by Service
      • 7.4.2.1 LAMEA Contract Manufacturing Market by Country
      • 7.4.2.2 LAMEA Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
        • 7.4.2.2.1 LAMEA Commercial Market by Country
        • 7.4.2.2.2 LAMEA Clinical Market by Country
      • 7.4.2.3 LAMEA Contract Development Market by Country
      • 7.4.2.4 LAMEA Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.4.2.4.1 LAMEA Cell Line Development Market by Country
        • 7.4.2.4.2 LAMEA Process Development Market by Country
    • 7.4.3 LAMEA Large Molecule Drug Substance CDMO Market by End-user
      • 7.4.3.1 LAMEA Biotech Companies Market by Country
      • 7.4.3.2 LAMEA CRO Market by Country
      • 7.4.3.3 LAMEA Others Market by Country
    • 7.4.4 LAMEA Large Molecule Drug Substance CDMO Market by Country
      • 7.4.4.1 Brazil Large Molecule Drug Substance CDMO Market
        • 7.4.4.1.1 Brazil Large Molecule Drug Substance CDMO Market by Application
        • 7.4.4.1.2 Brazil Large Molecule Drug Substance CDMO Market by Service
          • 7.4.4.1.2.1 Brazil Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.4.4.1.2.2 Brazil Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.4.4.1.3 Brazil Large Molecule Drug Substance CDMO Market by End-user
      • 7.4.4.2 Argentina Large Molecule Drug Substance CDMO Market
        • 7.4.4.2.1 Argentina Large Molecule Drug Substance CDMO Market by Application
        • 7.4.4.2.2 Argentina Large Molecule Drug Substance CDMO Market by Service
          • 7.4.4.2.2.1 Argentina Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.4.4.2.2.2 Argentina Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.4.4.2.3 Argentina Large Molecule Drug Substance CDMO Market by End-user
      • 7.4.4.3 UAE Large Molecule Drug Substance CDMO Market
        • 7.4.4.3.1 UAE Large Molecule Drug Substance CDMO Market by Application
        • 7.4.4.3.2 UAE Large Molecule Drug Substance CDMO Market by Service
          • 7.4.4.3.2.1 UAE Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.4.4.3.2.2 UAE Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.4.4.3.3 UAE Large Molecule Drug Substance CDMO Market by End-user
      • 7.4.4.4 Saudi Arabia Large Molecule Drug Substance CDMO Market
        • 7.4.4.4.1 Saudi Arabia Large Molecule Drug Substance CDMO Market by Application
        • 7.4.4.4.2 Saudi Arabia Large Molecule Drug Substance CDMO Market by Service
          • 7.4.4.4.2.1 Saudi Arabia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.4.4.4.2.2 Saudi Arabia Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.4.4.4.3 Saudi Arabia Large Molecule Drug Substance CDMO Market by End-user
      • 7.4.4.5 South Africa Large Molecule Drug Substance CDMO Market
        • 7.4.4.5.1 South Africa Large Molecule Drug Substance CDMO Market by Application
        • 7.4.4.5.2 South Africa Large Molecule Drug Substance CDMO Market by Service
          • 7.4.4.5.2.1 South Africa Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.4.4.5.2.2 South Africa Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.4.4.5.3 South Africa Large Molecule Drug Substance CDMO Market by End-user
      • 7.4.4.6 Nigeria Large Molecule Drug Substance CDMO Market
        • 7.4.4.6.1 Nigeria Large Molecule Drug Substance CDMO Market by Application
        • 7.4.4.6.2 Nigeria Large Molecule Drug Substance CDMO Market by Service
          • 7.4.4.6.2.1 Nigeria Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.4.4.6.2.2 Nigeria Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.4.4.6.3 Nigeria Large Molecule Drug Substance CDMO Market by End-user
      • 7.4.4.7 Rest of LAMEA Large Molecule Drug Substance CDMO Market
        • 7.4.4.7.1 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Application
        • 7.4.4.7.2 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Service
          • 7.4.4.7.2.1 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
          • 7.4.4.7.2.2 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Contract Development Type
        • 7.4.4.7.3 Rest of LAMEA Large Molecule Drug Substance CDMO Market by End-user

Chapter 8. Company Profiles

  • 8.1 Teledyne FLIR LLC (Teledyne Technologies Incorporated)
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Segmental and Regional Analysis
    • 8.1.4 Recent strategies and developments:
      • 8.1.4.1 Partnerships, Collaborations and Agreements:
      • 8.1.4.2 Product Launches and Product Expansions:
    • 8.1.5 SWOT Analysis
  • 8.2 Hikvision Digital Technology Co., Ltd., (China Electronics Technology Group Corporation)
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Research & Development Expenses
    • 8.2.4 Recent strategies and developments:
      • 8.2.4.1 Partnerships, Collaborations, and Agreements:
      • 8.2.4.2 Product Launches and Product Expansions:
  • 8.3 Axis Communications AB (Canon, Inc.)
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Segmental and Regional Analysis
    • 8.3.4 Research & Development Expenses
    • 8.3.5 Recent strategies and developments:
      • 8.3.5.1 Partnerships, Collaborations, and Agreements:
      • 8.3.5.2 Product Launches and Product Expansions:
  • 8.4 Bosch Security Systems GmbH (Robert Bosch GmbH)
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Segmental and Regional Analysis
    • 8.4.4 Research & Development Expense
    • 8.4.5 Recent strategies and developments:
      • 8.4.5.1 Product Launches and Product Expansions:
  • 8.5 Avigilon Corporation (Motorola Solutions)
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Regional & Segmental Analysis
    • 8.5.4 Research & Development Expenses
  • 8.6 Hanwha Techwin Co., Ltd. (Hanwha Group)
    • 8.6.1 Company Overview
    • 8.6.2 Recent strategies and developments:
      • 8.6.2.1 Partnerships, Collaborations, and Agreements:
      • 8.6.2.2 Product Launches and Product Expansions:
  • 8.7 Zhejiang Dahua Technology Co., Ltd.
    • 8.7.1 Company Overview
    • 8.7.2 Recent strategies and developments:
      • 8.7.2.1 Product Launches and Product Expansions:
  • 8.8 Zhejiang Uniview Technologies Co., Ltd. (Hangzhou Jiaozhi Technology Co., Ltd.)
    • 8.8.1 Company Overview
    • 8.8.2 Recent strategies and developments:
      • 8.8.2.1 Partnerships, Collaborations, and Agreements:

LIST OF TABLES

  • TABLE 1 Global Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 2 Global Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Large Molecule Drug Substance CDMO Market
  • TABLE 4 Acquisition and Mergers- Large Molecule Drug Substance CDMO Market
  • TABLE 5 Geographical Expansions - Large Molecule Drug Substance CDMO Market
  • TABLE 6 Global Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 7 Global Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 8 Global Mammalian Market by Region, 2018 - 2021, USD Million
  • TABLE 9 Global Mammalian Market by Region, 2022 - 2028, USD Million
  • TABLE 10 Global Microbial Market by Region, 2018 - 2021, USD Million
  • TABLE 11 Global Microbial Market by Region, 2022 - 2028, USD Million
  • TABLE 12 Global Other Application Market by Region, 2018 - 2021, USD Million
  • TABLE 13 Global Other Application Market by Region, 2022 - 2028, USD Million
  • TABLE 14 Global Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 15 Global Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 16 Global Contract Manufacturing Market by Region, 2018 - 2021, USD Million
  • TABLE 17 Global Contract Manufacturing Market by Region, 2022 - 2028, USD Million
  • TABLE 18 Global Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 19 Global Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 20 Global Commercial Market by Region, 2018 - 2021, USD Million
  • TABLE 21 Global Commercial Market by Region, 2022 - 2028, USD Million
  • TABLE 22 Global Clinical Market by Region, 2018 - 2021, USD Million
  • TABLE 23 Global Clinical Market by Region, 2022 - 2028, USD Million
  • TABLE 24 Global Contract Development Market by Region, 2018 - 2021, USD Million
  • TABLE 25 Global Contract Development Market by Region, 2022 - 2028, USD Million
  • TABLE 26 Global Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 27 Global Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 28 Global Cell Line Development Market by Region, 2018 - 2021, USD Million
  • TABLE 29 Global Cell Line Development Market by Region, 2022 - 2028, USD Million
  • TABLE 30 Global Process Development Market by Region, 2018 - 2021, USD Million
  • TABLE 31 Global Process Development Market by Region, 2022 - 2028, USD Million
  • TABLE 32 Global Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 33 Global Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 34 Global Biotech Companies Market by Region, 2018 - 2021, USD Million
  • TABLE 35 Global Biotech Companies Market by Region, 2022 - 2028, USD Million
  • TABLE 36 Global CRO Market by Region, 2018 - 2021, USD Million
  • TABLE 37 Global CRO Market by Region, 2022 - 2028, USD Million
  • TABLE 38 Global Others Market by Region, 2018 - 2021, USD Million
  • TABLE 39 Global Others Market by Region, 2022 - 2028, USD Million
  • TABLE 40 Global Large Molecule Drug Substance CDMO Market by Region, 2018 - 2021, USD Million
  • TABLE 41 Global Large Molecule Drug Substance CDMO Market by Region, 2022 - 2028, USD Million
  • TABLE 42 North America Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 43 North America Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 44 North America Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 45 North America Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 46 North America Mammalian Market by Country, 2018 - 2021, USD Million
  • TABLE 47 North America Mammalian Market by Country, 2022 - 2028, USD Million
  • TABLE 48 North America Microbial Market by Country, 2018 - 2021, USD Million
  • TABLE 49 North America Microbial Market by Country, 2022 - 2028, USD Million
  • TABLE 50 North America Other Application Market by Country, 2018 - 2021, USD Million
  • TABLE 51 North America Other Application Market by Country, 2022 - 2028, USD Million
  • TABLE 52 North America Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 53 North America Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 54 North America Contract Manufacturing Market by Country, 2018 - 2021, USD Million
  • TABLE 55 North America Contract Manufacturing Market by Country, 2022 - 2028, USD Million
  • TABLE 56 North America Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 57 North America Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 58 North America Commercial Market by Country, 2018 - 2021, USD Million
  • TABLE 59 North America Commercial Market by Country, 2022 - 2028, USD Million
  • TABLE 60 North America Clinical Market by Country, 2018 - 2021, USD Million
  • TABLE 61 North America Clinical Market by Country, 2022 - 2028, USD Million
  • TABLE 62 North America Contract Development Market by Country, 2018 - 2021, USD Million
  • TABLE 63 North America Contract Development Market by Country, 2022 - 2028, USD Million
  • TABLE 64 North America Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 65 North America Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 66 North America Cell Line Development Market by Country, 2018 - 2021, USD Million
  • TABLE 67 North America Cell Line Development Market by Country, 2022 - 2028, USD Million
  • TABLE 68 North America Process Development Market by Country, 2018 - 2021, USD Million
  • TABLE 69 North America Process Development Market by Country, 2022 - 2028, USD Million
  • TABLE 70 North America Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 71 North America Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 72 North America Biotech Companies Market by Country, 2018 - 2021, USD Million
  • TABLE 73 North America Biotech Companies Market by Country, 2022 - 2028, USD Million
  • TABLE 74 North America CRO Market by Country, 2018 - 2021, USD Million
  • TABLE 75 North America CRO Market by Country, 2022 - 2028, USD Million
  • TABLE 76 North America Others Market by Country, 2018 - 2021, USD Million
  • TABLE 77 North America Others Market by Country, 2022 - 2028, USD Million
  • TABLE 78 North America Large Molecule Drug Substance CDMO Market by Country, 2018 - 2021, USD Million
  • TABLE 79 North America Large Molecule Drug Substance CDMO Market by Country, 2022 - 2028, USD Million
  • TABLE 80 US Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 81 US Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 82 US Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 83 US Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 84 US Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 85 US Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 86 US Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 87 US Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 88 US Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 89 US Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 90 US Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 91 US Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 92 Canada Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 93 Canada Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 94 Canada Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 95 Canada Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 96 Canada Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 97 Canada Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 98 Canada Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 99 Canada Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 100 Canada Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 101 Canada Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 102 Canada Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 103 Canada Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 104 Mexico Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 105 Mexico Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 106 Mexico Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 107 Mexico Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 108 Mexico Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 109 Mexico Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 110 Mexico Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 111 Mexico Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 112 Mexico Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 113 Mexico Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 114 Mexico Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 115 Mexico Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 116 Rest of North America Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 117 Rest of North America Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 118 Rest of North America Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 119 Rest of North America Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 120 Rest of North America Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 121 Rest of North America Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 122 Rest of North America Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 123 Rest of North America Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 124 Rest of North America Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 125 Rest of North America Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 126 Rest of North America Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 127 Rest of North America Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 128 Europe Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 129 Europe Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 130 Europe Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 131 Europe Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 132 Europe Mammalian Market by Country, 2018 - 2021, USD Million
  • TABLE 133 Europe Mammalian Market by Country, 2022 - 2028, USD Million
  • TABLE 134 Europe Microbial Market by Country, 2018 - 2021, USD Million
  • TABLE 135 Europe Microbial Market by Country, 2022 - 2028, USD Million
  • TABLE 136 Europe Other Application Market by Country, 2018 - 2021, USD Million
  • TABLE 137 Europe Other Application Market by Country, 2022 - 2028, USD Million
  • TABLE 138 Europe Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 139 Europe Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 140 Europe Contract Manufacturing Market by Country, 2018 - 2021, USD Million
  • TABLE 141 Europe Contract Manufacturing Market by Country, 2022 - 2028, USD Million
  • TABLE 142 Europe Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 143 Europe Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 144 Europe Commercial Market by Country, 2018 - 2021, USD Million
  • TABLE 145 Europe Commercial Market by Country, 2022 - 2028, USD Million
  • TABLE 146 Europe Clinical Market by Country, 2018 - 2021, USD Million
  • TABLE 147 Europe Clinical Market by Country, 2022 - 2028, USD Million
  • TABLE 148 Europe Contract Development Market by Country, 2018 - 2021, USD Million
  • TABLE 149 Europe Contract Development Market by Country, 2022 - 2028, USD Million
  • TABLE 150 Europe Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 151 Europe Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 152 Europe Cell Line Development Market by Country, 2018 - 2021, USD Million
  • TABLE 153 Europe Cell Line Development Market by Country, 2022 - 2028, USD Million
  • TABLE 154 Europe Process Development Market by Country, 2018 - 2021, USD Million
  • TABLE 155 Europe Process Development Market by Country, 2022 - 2028, USD Million
  • TABLE 156 Europe Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 157 Europe Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 158 Europe Biotech Companies Market by Country, 2018 - 2021, USD Million
  • TABLE 159 Europe Biotech Companies Market by Country, 2022 - 2028, USD Million
  • TABLE 160 Europe CRO Market by Country, 2018 - 2021, USD Million
  • TABLE 161 Europe CRO Market by Country, 2022 - 2028, USD Million
  • TABLE 162 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 163 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 164 Europe Large Molecule Drug Substance CDMO Market by Country, 2018 - 2021, USD Million
  • TABLE 165 Europe Large Molecule Drug Substance CDMO Market by Country, 2022 - 2028, USD Million
  • TABLE 166 Germany Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 167 Germany Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 168 Germany Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 169 Germany Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 170 Germany Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 171 Germany Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 172 Germany Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 173 Germany Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 174 Germany Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 175 Germany Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 176 Germany Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 177 Germany Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 178 UK Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 179 UK Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 180 UK Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 181 UK Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 182 UK Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 183 UK Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 184 UK Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 185 UK Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 186 UK Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 187 UK Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 188 UK Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 189 UK Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 190 France Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 191 France Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 192 France Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 193 France Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 194 France Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 195 France Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 196 France Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 197 France Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 198 France Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 199 France Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 200 France Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 201 France Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 202 Russia Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 203 Russia Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 204 Russia Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 205 Russia Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 206 Russia Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 207 Russia Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 208 Russia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 209 Russia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 210 Russia Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 211 Russia Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 212 Russia Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 213 Russia Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 214 Spain Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 215 Spain Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 216 Spain Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 217 Spain Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 218 Spain Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 219 Spain Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 220 Spain Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 221 Spain Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 222 Spain Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 223 Spain Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 224 Spain Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 225 Spain Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 226 Italy Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 227 Italy Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 228 Italy Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 229 Italy Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 230 Italy Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 231 Italy Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 232 Italy Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 233 Italy Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 234 Italy Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 235 Italy Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 236 Italy Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 237 Italy Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 238 Rest of Europe Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 239 Rest of Europe Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 240 Rest of Europe Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 241 Rest of Europe Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 242 Rest of Europe Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 243 Rest of Europe Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 244 Rest of Europe Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 245 Rest of Europe Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 246 Rest of Europe Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 247 Rest of Europe Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 248 Rest of Europe Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 249 Rest of Europe Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 250 Asia Pacific Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 251 Asia Pacific Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 252 Asia Pacific Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 253 Asia Pacific Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 254 Asia Pacific Mammalian Market by Country, 2018 - 2021, USD Million
  • TABLE 255 Asia Pacific Mammalian Market by Country, 2022 - 2028, USD Million
  • TABLE 256 Asia Pacific Microbial Market by Country, 2018 - 2021, USD Million
  • TABLE 257 Asia Pacific Microbial Market by Country, 2022 - 2028, USD Million
  • TABLE 258 Asia Pacific Other Application Market by Country, 2018 - 2021, USD Million
  • TABLE 259 Asia Pacific Other Application Market by Country, 2022 - 2028, USD Million
  • TABLE 260 Asia Pacific Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 261 Asia Pacific Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 262 Asia Pacific Contract Manufacturing Market by Country, 2018 - 2021, USD Million
  • TABLE 263 Asia Pacific Contract Manufacturing Market by Country, 2022 - 2028, USD Million
  • TABLE 264 Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 265 Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 266 Asia Pacific Commercial Market by Country, 2018 - 2021, USD Million
  • TABLE 267 Asia Pacific Commercial Market by Country, 2022 - 2028, USD Million
  • TABLE 268 Asia Pacific Clinical Market by Country, 2018 - 2021, USD Million
  • TABLE 269 Asia Pacific Clinical Market by Country, 2022 - 2028, USD Million
  • TABLE 270 Asia Pacific Contract Development Market by Country, 2018 - 2021, USD Million
  • TABLE 271 Asia Pacific Contract Development Market by Country, 2022 - 2028, USD Million
  • TABLE 272 Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 273 Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 274 Asia Pacific Cell Line Development Market by Country, 2018 - 2021, USD Million
  • TABLE 275 Asia Pacific Cell Line Development Market by Country, 2022 - 2028, USD Million
  • TABLE 276 Asia Pacific Process Development Market by Country, 2018 - 2021, USD Million
  • TABLE 277 Asia Pacific Process Development Market by Country, 2022 - 2028, USD Million
  • TABLE 278 Asia Pacific Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 279 Asia Pacific Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 280 Asia Pacific Biotech Companies Market by Country, 2018 - 2021, USD Million
  • TABLE 281 Asia Pacific Biotech Companies Market by Country, 2022 - 2028, USD Million
  • TABLE 282 Asia Pacific CRO Market by Country, 2018 - 2021, USD Million
  • TABLE 283 Asia Pacific CRO Market by Country, 2022 - 2028, USD Million
  • TABLE 284 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 285 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 286 Asia Pacific Large Molecule Drug Substance CDMO Market by Country, 2018 - 2021, USD Million
  • TABLE 287 Asia Pacific Large Molecule Drug Substance CDMO Market by Country, 2022 - 2028, USD Million
  • TABLE 288 China Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 289 China Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 290 China Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 291 China Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 292 China Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 293 China Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 294 China Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 295 China Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 296 China Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 297 China Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 298 China Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 299 China Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 300 Japan Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 301 Japan Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 302 Japan Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 303 Japan Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 304 Japan Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 305 Japan Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 306 Japan Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 307 Japan Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 308 Japan Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 309 Japan Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 310 Japan Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 311 Japan Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 312 India Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 313 India Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 314 India Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 315 India Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 316 India Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 317 India Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 318 India Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 319 India Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 320 India Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 321 India Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 322 India Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 323 India Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 324 South Korea Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 325 South Korea Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 326 South Korea Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 327 South Korea Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 328 South Korea Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 329 South Korea Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 330 South Korea Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 331 South Korea Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 332 South Korea Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 333 South Korea Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 334 South Korea Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 335 South Korea Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 336 Singapore Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 337 Singapore Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 338 Singapore Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 339 Singapore Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 340 Singapore Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 341 Singapore Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 342 Singapore Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 343 Singapore Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 344 Singapore Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 345 Singapore Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 346 Singapore Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 347 Singapore Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 348 Malaysia Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 349 Malaysia Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 350 Malaysia Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 351 Malaysia Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 352 Malaysia Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 353 Malaysia Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 354 Malaysia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 355 Malaysia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 356 Malaysia Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 357 Malaysia Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 358 Malaysia Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 359 Malaysia Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 360 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 361 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 362 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 363 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 364 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 365 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 366 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 367 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 368 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 369 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 370 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 371 Rest of Asia Pacific Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 372 LAMEA Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 373 LAMEA Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 374 LAMEA Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 375 LAMEA Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 376 LAMEA Mammalian Market by Country, 2018 - 2021, USD Million
  • TABLE 377 LAMEA Mammalian Market by Country, 2022 - 2028, USD Million
  • TABLE 378 LAMEA Microbial Market by Country, 2018 - 2021, USD Million
  • TABLE 379 LAMEA Microbial Market by Country, 2022 - 2028, USD Million
  • TABLE 380 LAMEA Other Application Market by Country, 2018 - 2021, USD Million
  • TABLE 381 LAMEA Other Application Market by Country, 2022 - 2028, USD Million
  • TABLE 382 LAMEA Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 383 LAMEA Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 384 LAMEA Contract Manufacturing Market by Country, 2018 - 2021, USD Million
  • TABLE 385 LAMEA Contract Manufacturing Market by Country, 2022 - 2028, USD Million
  • TABLE 386 LAMEA Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 387 LAMEA Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 388 LAMEA Commercial Market by Country, 2018 - 2021, USD Million
  • TABLE 389 LAMEA Commercial Market by Country, 2022 - 2028, USD Million
  • TABLE 390 LAMEA Clinical Market by Country, 2018 - 2021, USD Million
  • TABLE 391 LAMEA Clinical Market by Country, 2022 - 2028, USD Million
  • TABLE 392 LAMEA Contract Development Market by Country, 2018 - 2021, USD Million
  • TABLE 393 LAMEA Contract Development Market by Country, 2022 - 2028, USD Million
  • TABLE 394 LAMEA Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 395 LAMEA Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 396 LAMEA Cell Line Development Market by Country, 2018 - 2021, USD Million
  • TABLE 397 LAMEA Cell Line Development Market by Country, 2022 - 2028, USD Million
  • TABLE 398 LAMEA Process Development Market by Country, 2018 - 2021, USD Million
  • TABLE 399 LAMEA Process Development Market by Country, 2022 - 2028, USD Million
  • TABLE 400 LAMEA Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 401 LAMEA Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 402 LAMEA Biotech Companies Market by Country, 2018 - 2021, USD Million
  • TABLE 403 LAMEA Biotech Companies Market by Country, 2022 - 2028, USD Million
  • TABLE 404 LAMEA CRO Market by Country, 2018 - 2021, USD Million
  • TABLE 405 LAMEA CRO Market by Country, 2022 - 2028, USD Million
  • TABLE 406 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 407 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 408 LAMEA Large Molecule Drug Substance CDMO Market by Country, 2018 - 2021, USD Million
  • TABLE 409 LAMEA Large Molecule Drug Substance CDMO Market by Country, 2022 - 2028, USD Million
  • TABLE 410 Brazil Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 411 Brazil Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 412 Brazil Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 413 Brazil Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 414 Brazil Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 415 Brazil Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 416 Brazil Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 417 Brazil Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 418 Brazil Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 419 Brazil Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 420 Brazil Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 421 Brazil Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 422 Argentina Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 423 Argentina Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 424 Argentina Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 425 Argentina Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 426 Argentina Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 427 Argentina Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 428 Argentina Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 429 Argentina Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 430 Argentina Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 431 Argentina Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 432 Argentina Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 433 Argentina Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 434 UAE Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 435 UAE Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 436 UAE Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 437 UAE Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 438 UAE Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 439 UAE Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 440 UAE Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 441 UAE Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 442 UAE Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 443 UAE Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 444 UAE Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 445 UAE Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 446 Saudi Arabia Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 447 Saudi Arabia Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 448 Saudi Arabia Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 449 Saudi Arabia Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 450 Saudi Arabia Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 451 Saudi Arabia Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 452 Saudi Arabia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 453 Saudi Arabia Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 454 Saudi Arabia Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 455 Saudi Arabia Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 456 Saudi Arabia Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 457 Saudi Arabia Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 458 South Africa Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 459 South Africa Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 460 South Africa Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 461 South Africa Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 462 South Africa Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 463 South Africa Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 464 South Africa Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 465 South Africa Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 466 South Africa Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 467 South Africa Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 468 South Africa Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 469 South Africa Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 470 Nigeria Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 471 Nigeria Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 472 Nigeria Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 473 Nigeria Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 474 Nigeria Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 475 Nigeria Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 476 Nigeria Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 477 Nigeria Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 478 Nigeria Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 479 Nigeria Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 480 Nigeria Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 481 Nigeria Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 482 Rest of LAMEA Large Molecule Drug Substance CDMO Market, 2018 - 2021, USD Million
  • TABLE 483 Rest of LAMEA Large Molecule Drug Substance CDMO Market, 2022 - 2028, USD Million
  • TABLE 484 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Application, 2018 - 2021, USD Million
  • TABLE 485 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Application, 2022 - 2028, USD Million
  • TABLE 486 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Service, 2018 - 2021, USD Million
  • TABLE 487 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Service, 2022 - 2028, USD Million
  • TABLE 488 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2018 - 2021, USD Million
  • TABLE 489 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type, 2022 - 2028, USD Million
  • TABLE 490 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Contract Development Type, 2018 - 2021, USD Million
  • TABLE 491 Rest of LAMEA Large Molecule Drug Substance CDMO Market by Contract Development Type, 2022 - 2028, USD Million
  • TABLE 492 Rest of LAMEA Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2021, USD Million
  • TABLE 493 Rest of LAMEA Large Molecule Drug Substance CDMO Market by End-user, 2022 - 2028, USD Million
  • TABLE 494 Key Information - Teledyne FLIR LLC
  • TABLE 495 Key Information - Hikvision Digital Technology Co., Ltd.,
  • TABLE 496 Key Information - Axis Communications AB
  • TABLE 497 Key Information - Bosch Security Systems GmbH
  • TABLE 498 Key Information - Avigilon Corporation
  • TABLE 499 Key Information - Hanwha Techwin Co., Ltd.
  • TABLE 500 Key Information - Zhejiang Dahua Technology Co., Ltd.
  • TABLE 501 Key Information - Zhejiang Uniview Technologies Co., Ltd.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
  • FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2019, APR - 2022, Oct) Leading Players
  • FIG 5 Key Strategic Move: (Acquisitions and Mergers : 2018, Oct - 2022, Aug) Leading Players
  • FIG 6 Global Large Molecule Drug Substance CDMO Market Share by Application, 2021
  • FIG 7 Global Large Molecule Drug Substance CDMO Market Share by Application, 2028
  • FIG 8 Global Large Molecule Drug Substance CDMO Market by Application, 2018 - 2028, USD Million
  • FIG 9 Global Large Molecule Drug Substance CDMO Market Share by Service, 2021
  • FIG 10 Global Large Molecule Drug Substance CDMO Market Share by Service, 2028
  • FIG 11 Global Large Molecule Drug Substance CDMO Market by Service, 2018 - 2028, USD Million
  • FIG 12 Global Large Molecule Drug Substance CDMO Market Share by End-user, 2021
  • FIG 13 Global Large Molecule Drug Substance CDMO Market Share by End-user, 2028
  • FIG 14 Global Large Molecule Drug Substance CDMO Market by End-user, 2018 - 2028, USD Million
  • FIG 15 Global Large Molecule Drug Substance CDMO Market Share by Region, 2021
  • FIG 16 Global Large Molecule Drug Substance CDMO Market Share by Region, 2028
  • FIG 17 Global Large Molecule Drug Substance CDMO Market by Region, 2018 - 2028, USD Million
  • FIG 18 Recent strategies and developments: Teledyne FLIR LLC
  • FIG 19 Swot analysis: Teledyne FLIR LLC
  • FIG 20 Recent strategies and developments: Hikvision Digital Technology Co., Ltd.
  • FIG 21 Recent strategies and developments: Axis Communications AB
  • FIG 22 Recent strategies and developments: Hanwha Techwin Co., Ltd.